【レポートの概要(一部)】
1. Report Overview
1.1 Overview of the World Next-Generation Biologics Market
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biologics
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2015-2025
3.1 The Next-Generation Biologics Market 2014
3.1.1 Development of the Next-Generation Biologics Market 2008-2014
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2014
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2014
3.2 The Next-Generation Biologics Market 2015-2025
3.2.1 Growth Drivers for Biological Drug Revenues 2015-2025
3.2.2 The Next-Generation Biologics Market Forecast 2015-2025
3.2.3 Product Launches in All Sectors to Drive Market Growth 2015-2025
3.2.4 Next-Generation Biologics: Market Restraints 2015-2025
3.2.5 Rising Market Shares for Next-Generation Insulins 2015-2025
4. Leading National Submarkets for Next-Generation Biologics 2015-2025
4.1 Leading National Submarkets for Next-Generation Biologics 2014
4.1.1 National Submarket Forecasts 2015-2025
4.1.2 How Will National Submarket Shares Change to 2025?
4.2 Rising Disease Incidence in Important Markets 2015-2025
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2015-2025
4.4.1 US Submarket Forecast 2015-2025
4.5 Next-Generation Biologics in Japan 2015-2025
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2015-2025
4.6 Next-Generation Biologics in Leading EU Countries 2015-2025
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2015-2025
4.6.4 France: Submarket Forecast 2015-2025
4.6.5 UK: Submarket Forecast 2015-2025
4.6.6 Italy and Spain: Submarket Forecasts 2015-2025
4.7 Next-Generation Biologics in Emerging Markets 2015-2025
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2015-2025
4.7.3 Indian Submarket Forecast 2015-2025
5. Next-Generation Antibodies Submarket Outlooks 2015-2025
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket 2013-2014
5.3 Next-Generation Antibody Therapy Submarket 2015-2025
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2015-2025
5.3.2 Blockbuster Potential Will Drive Growth to 2025: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2015-2025
5.4 Antibody-Drug Conjugates (ADC) Submarket 2015-2025
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2015-2025
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2015-2025
5.4.2 What Will Drive Growth for ADCs to 2025?
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2015-2025
5.5.1 Engineered Antibodies Submarket Forecast 2015-2025
5.5.1.1 Gazyva Will Lead the Submarket in 2025
5.5.2 Portfolio Management to Drive Growth 2015-2025
5.5.3 Engineered Antibodies Pipeline 2015
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2015-2025
5.6.1 Bispecific Antibodies Submarket Forecast 2015-2025
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2015-2025
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2015
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-Like Drugs: Commercial Potential 2015-2025
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There Are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2015-2025
6.2.1 Antibody Fragment and ALP Submarket Forecast 2015-2025
6.2.2 Pharma Is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2025
6.3 Outlook for Next-Generation Antibody Fragments 2015-2025
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2015-2025
6.3.2 One Platform Leads the Pipeline in 2015
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2015-2025
6.4.1 Antibody-Like Protein Submarket Forecast 2015-2025
6.4.2 Four ALPs in Clinical Development in 2014
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2025?
6.5.1 Challenges with First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2014
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2015-2025
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2012-2014
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2015-2025
7.3 Next-Generation Insulin Submarket 2015-2025
7.3.1 Next-Generation Insulin Submarket Forecast 2015-2025
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2015-2025
7.3.3 Next-Generation Insulin Submarket Restraints 2015-2025
7.3.3.1 Biosimilar Insulins Will be Available from 2015
7.4 Oral Insulin Submarket 2015-2025
7.4.1 Oral Insulin Submarket Forecast 2015-2025
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2015-2025
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2014
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2015-2025
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2015-2025
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2025?
7.5.2 Other Submarket Drivers and Restraints 2015-2025
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2014
7.5.3.1 FIAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2015-2025
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2015-2025
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2015
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LY2605541 (Eli Lilly)
7.6.3.3 FT-105 (Flamel Technologies)
7.6.3.4 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2015-2025
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Set for Approval in 2014
8.1.1.1 Plegridy: Revenue Forecast 2015-2025
8.1.1.2 Plegridy May Compete with Other Long-Acting Interferon Beta Therapies 2015-2025
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2014
8.2 Next-Generation Recombinant Coagulation Factors 2015-2025
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2015-2025
8.2.2 Submarket Drivers and Restraints 2015-2025
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2015-2025
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rIX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2015-2025
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2015-2025
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormones 2015-2025
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2015-2025
9.1 The Regenerative Medicine Submarket 2012-2014
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2015-2025
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2015-2025
9.3 The Stem Cell Therapies Submarket 2015-2025
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2015-2025
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2015-2025
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2015
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2015-2025
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Will Market Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2015-2025
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2015-2025
9.4.4 Future Developments in Cartilage Repair: Pipeline 2015
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2015-2025
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2015-2025
9.5.3 Glybera’s Approval to Drive Submarket Growth from 2014
9.5.4 There Are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2015-2025
10.1 Next-Generation Biologics: Market Strengths 2014
10.2 Next-Generation Biologics: Market Weaknesses 2014
10.3 The Next-Generation Biologics Market: STEP Analysis 2015-2025
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2015-2025
10.3.3 Economic Pressures 2015-2025
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2015-2025
10.4 Next-Generation Biologics: Development Trends 2015-2025
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2015-2025
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenges with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2015-2025
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann; VP of Research, Dr Kouros Motamed; VP, Strategic Alliances and Clinical Communications and George Uy; EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from the Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2025
12.1.1 Next-Generation Antibody Development Will Lead the Market
12.2 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.3 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル:次世代生物製剤の世界市場:抗体、再生医療、抗体断片/ALP、インスリン、組換え型血液凝固因子、成長ホルモン■ 英文:Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025
■ 発行日:2015年5月
■ 調査会社:visiongain
■ 商品コード:VGAIN5052608
■ 調査対象地域:グローバル
- 世界のオンライン広告支出市場動向(2012-2016)TechNavio's analysts forecast the Global Online Ad Spending market to grow at a CAGR of 11.54 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in online ad spending. The Global Online Ad Spending market has also been witnessing a shift from direct response advertising to brand advertising. However, data security concerns could pose a chal …
- ワクチン開発戦略Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is increasingl …
- 世界の魚及びシーフード市場:ニュース、イベント動向(2014年3月)Synopsis The report provides a review of the latest news and key events in the global fish & seafood market during March 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global fish & seafood market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in th …
- アブレーション技術(アブレータ/切除装置)の世界市場:レーザー/光アブレーション、高周波アブレーション、超音波アブレーション等The global ablation technologies market is estimated to grow at a CAGR of 9.6% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the ablation technologies market in 2014, the Asia-Pacific region is poised to grow at the highest CAGR of 12.8% in the next five years. Factors such as increasing government initiatives for modernization o …
- パワーオーバーイーサネット(PoE)チップセットの世界市場:タイプ別(PSEチップセット、PDチップセット)、規格別(802.3bt、802.3at、802.3af) 、用途別(LED照明、セキュリティ、インフォテイメント、コネクティビティ)、エンドユーザー別(住宅、商業、工業)、デバイスタイプ別(VoIP電話、近接センサー、ネットワークカメラ、その他)、地域別予測Global Power over Ethernet (PoE) Chipsets Market to reach USD 1.2 billion by 2025. Global Power over Ethernet (PoE) Chipsets Market valued approximately USD 430 million in 2016 is forecasted to grow with a healthy growth rate of more than 12.12% over the forecast period 2018-2025. The major factors predicted to augment the market are escalating requirements for PoE chipsets in connectivity, securi …
- パターニング材料の世界市場:ポジ型193NM液浸レジスト、ポジ型193NMドライレジスト、ポジ型248NMレジスト、Iライン/GラインレジストPatterning refers to a method of photolithography to build integrated circuits on wafers in the electronic device fabrication process. Patterning materials refer to polymer films, also called as photoresist, on which the desired pattern is deposited through exposure of light of specific wavelength. Patterning materials are basically used in the process of manufacturing printed circuit boards. Patt …
- 鉄道車両の世界市場:機関車、高速輸送車両、旅客車、貨車The demand for rolling stock depends on economic development of the country and the government support to develop the country’s infrastructure. The rolling stock market is governed by urbanization following population growth and economic development in emerging nations. The global economic meltdown from 2008–2013 has slowed down growth. However, the long-term outlook of the rail transportation ind …
- フォグコンピューティングの世界市場分析:ソリューション別、ハードウェア別(ゲートウェイ、ルーター・スイッチ、センサ)、用途別(コネクテッドビークル、スマートグリッド、スマートシティ、コネクテッドヘルスケア、スマート製造)、地域別、セグメント予測、2016 – 2025The global fog computing market is expected to reach USD 617.3 million by 2025, according to a new report by Grand View Research, Inc. The increasing demand from end-use industries is expected to propel the industry growth. Fog computing is an advancement in Internet of Things (IoT) that has shifted data processing out of the cloud into devices. With the growing number of IoT deployments, the amou …
- 世界のアクティブ光ケーブル市場2015The Global Active Optical Cables Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Active Optical Cables industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Active Optical Cables market analysis is provided for the international markets including deve …
- 包装用ロボットの世界市場2016-2020About Packaging Robots Packaging is a process of wrapping or covering a product to protect and preserve its inert quality from the risk of contamination or damage during its entire journey from the manufacturing site to the customer location. Good packaging promotes ease of transportation and storage. In addition, it shows essential information about the product. Thus packaging assumes a critical …
- インテリジェントパワーディストリビューションユニット(PDU)の世界市場2019-2023Global Intelligent Power Distribution Unit (PDU) Market: About this market Technavio’s intelligent power distribution unit (PDU) market analysis considers sales from data centers, industrial power solutions, and VoIP phone systems. Our analysis also considers the sales of intelligent power distribution unit (PDU) in APAC, Europe, North America, South America, and MEA. In 2018, the data centers seg …
- 産業用制御スイッチの世界市場:リミットスイッチ、回転式スイッチ、押しボタンAbout Industrial Control Switches Limit switches are the fastest growing segment and account for nearly half of the overall industrial control switches market. End-users prefer switches that hold certifications, such as European Union (CE certification) and Canadian Standards Association (CSA), to prevent factory accidents and frequent switch failures. However, these certification preferences tend …
- クラウド請求サービスの世界市場2015-2019About Cloud Billing Services Billing management systems enable telecom operators to effectively handle all tasks and processes related to financial transactions. It facilitates customer account operations and provides invoicing flexibility for multiple payment models, methods, and channels. It also supplies tools for personalization of billing services and customized invoice calculation. It also e …
- 燃料電池の世界市場:PEMFC、SOFC、MCFC、DMFCAbout Fuel Cell Fuel cells produce electricity by utilizing the power generated from electrochemical reactions. They use external sources of chemical energy such as hydrogen and oxygen to produce energy. Electrochemical reactions in the fuel cells oxidize hydrogen, which reacts with oxygen to form water and release electrons. The electrons then flow through the external circuit producing an electr …
- 世界のマネージドプリントサービス(MPS: Managed Print Services)市場動向(2012-2016)TechNavio's analysts forecast the Global Managed Print Services (MPS) market to grow at a CAGR of 10.75 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need for significant cost reduction. The Global Managed Print Services (MPS) market has also been witnessing the increase in demand for cloud service offerings. However, the lack of transparency o …